Metabolic Dysfunction-Associated Steatotic Liver Disease study: ALN-CIDEB
Official title Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ClinicalTrials.gov ID: NCT07854782
What this study is testing
What is ALN-CIDEB?
an investigational drug being studied as a potential treatment for metabolic dysfunction-associated steatotic liver disease (MASH).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out if the drug ALN-CIDEB can reduce liver fat, injury, and scarring. It also looks for any side effects and how the drug affects the body.
- Who it's for
- Adults who have a liver condition called metabolic dysfunction-associated steatotic liver disease (MASLD).
- What's involved
- Participants will receive the study drug and undergo tests to check liver health, such as scans or blood work, to monitor changes in fat and scarring.
- Time commitment
- The source text does not specify the total duration or the number of visits required.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Has a clinical diagnosis of MASLD, as defined in the protocol
- Has a liver stiffness measurement between 6 and 20 kilopascals (kPa), as measured by a FibroScan® scan during screening or within approximately 3...
You likely can't join if
- Has a known chronic liver disease other than MASLD, as determined by the investigator, as defined in the protocol
- Has prior or current suspected or known drug-induced liver injury within approximately 1 year prior to screening
- Has a history of liver transplantation, current placement on a liver transplant list, or Model for End-Stage Liver Disease (MELD) score \>12
- Has a known history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion
- Has prior, current, or planned future use (during the treatment period) of a GLP-1 receptor agonist-based therapy or any medication approved for the...
- Has evidence of uncontrolled human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection...
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
- Marrero, Louisiana, United States
- Metairie, Louisiana, United States
- Georgetown, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States; Marrero, Louisiana, United States; Metairie, Louisiana, United States; Georgetown, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.